NEW YORK, May 17, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Neurotrope, Inc. (“Neurotrope”) (NASDAQ:NTRP) between January 7, 2016, and April 28, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Hinshaw v. Neurotrope, Inc., et al. (Case No. 1:17-cv-03718) in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/neurotrope-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Take Action: if you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 



